Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity
- PMID: 22308483
- PMCID: PMC3309758
- DOI: 10.1073/pnas.1121383109
Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity
Abstract
For prevention of Streptococcus pneumoniae (pneumococcus) infections in infancy, protein-conjugated capsular polysaccharide vaccines provide serotype-specific, antibody-mediated immunity but do not cover all of the 90+ capsule serotypes. Therefore, microbiologists have sought protective noncapsular antigens common to all strains. Alternatively, we investigated killed cells of a noncapsulated strain, which expose many such common antigens. Given to mice intranasally, this vaccine elicits antibody-independent, CD4+ T lymphocyte-dependent accelerated clearance of pneumococci of various serotypes from the nasopharynx mediated by the cytokine IL-17A. Such immunity may reproduce the natural resistance that develops in infants before capsular antibodies arise. Given by injection, the killed cell vaccine induces bifunctional immunity: plasma antibodies protective against fatal pneumonia challenge, as well as IL-17A-mediated nasopharyngeal clearance. Human testing of this inexpensive candidate vaccine by intramuscular injection is planned. Bacterial cellular vaccines are complex--a challenge for reproducibility. However, when several known protective antigens were deleted, the killed pneumococcal vaccine was still protective. This antigenic redundancy may prevent vaccine escape variants by recombinational loss, which is frequent in pneumococcus. Biochemically defined immunogens with bifunctional activity have also been devised. These immunogens are three-component conjugates in which cell wall teichoic acid (a common antigen capable of T cell activation) is coupled to a genetic fusion of two common pneumococcal proteins: a protective surface antigen and a derivative of pneumolysin, which provides TLR4 agonist activity and induces antitoxic immunity. Such constructs induce accelerated clearance when given intranasally and induce both immune mechanisms when injected. The defined composition permits analysis of structure-function activity.
Conflict of interest statement
Conflict of interest statement: R.M. is a member of the scientific board of Genocea Biosciences.
Similar articles
-
Intranasal Immunization with the Commensal Streptococcus mitis Confers Protective Immunity against Pneumococcal Lung Infection.Appl Environ Microbiol. 2019 Mar 6;85(6):e02235-18. doi: 10.1128/AEM.02235-18. Print 2019 Mar 15. Appl Environ Microbiol. 2019. PMID: 30683742 Free PMC article.
-
Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide.Infect Immun. 2009 May;77(5):2076-83. doi: 10.1128/IAI.01554-08. Epub 2009 Mar 2. Infect Immun. 2009. PMID: 19255193 Free PMC article.
-
Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide.Infect Immun. 2006 Apr;74(4):2187-95. doi: 10.1128/IAI.74.4.2187-2195.2006. Infect Immun. 2006. PMID: 16552049 Free PMC article.
-
Mechanisms of Naturally Acquired Immunity to Streptococcus pneumoniae.Front Immunol. 2019 Mar 1;10:358. doi: 10.3389/fimmu.2019.00358. eCollection 2019. Front Immunol. 2019. PMID: 30881363 Free PMC article. Review.
-
Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development.J Mol Med (Berl). 2010 Feb;88(2):135-42. doi: 10.1007/s00109-009-0579-4. Epub 2010 Jan 5. J Mol Med (Berl). 2010. PMID: 20049411 Review.
Cited by
-
Th17 cell based vaccines in mucosal immunity.Curr Opin Immunol. 2013 Jun;25(3):373-80. doi: 10.1016/j.coi.2013.03.011. Epub 2013 May 10. Curr Opin Immunol. 2013. PMID: 23669353 Free PMC article. Review.
-
Corrected and Republished from: "A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Streptococcus pneumoniae Challenge".Infect Immun. 2022 Jan 25;90(1):e0084618a. doi: 10.1128/IAI.00846-18a. Epub 2018 Dec 10. Infect Immun. 2022. PMID: 35076289 Free PMC article.
-
Activation of memory Th17 cells by domain 4 pneumolysin in human nasopharynx-associated lymphoid tissue and its association with pneumococcal carriage.Mucosal Immunol. 2014 May;7(3):705-17. doi: 10.1038/mi.2013.89. Epub 2013 Nov 13. Mucosal Immunol. 2014. PMID: 24220296
-
Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.Clin Vaccine Immunol. 2014 May;21(5):651-60. doi: 10.1128/CVI.00807-13. Epub 2014 Mar 5. Clin Vaccine Immunol. 2014. PMID: 24599529 Free PMC article. Clinical Trial.
-
Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination.J R Soc Interface. 2017 Nov;14(136):20170620. doi: 10.1098/rsif.2017.0620. J R Soc Interface. 2017. PMID: 29093131 Free PMC article.
References
-
- O'Brien KL, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates. Lancet. 2009;374:893–902. - PubMed
-
- Tomasz A. Choline in the cell wall of a bacterium: Novel type of polymer-linked choline in Pneumococcus. Science. 1967;157:694–697. - PubMed
-
- Tomasz A. Surface components of Streptococcus pneumoniae. Rev Infect Dis. 1981;3:190–211. - PubMed
-
- Tuomanen E, Tomasz A, Hengstler B, Zak O. The relative role of bacterial cell wall and capsule in the induction of inflammation in pneumococcal meningitis. J Infect Dis. 1985;151:535–540. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials